Medical technology company Imperative Care announced that it has raised an oversubscribed Series E funding round led by Ally Bridge Group, which the company said could bring its Series E funding to $150 million if further rounds are completed.
Existing investors AMED Ventures, D1 Capital Partners, Rock Springs Capital Management, Bain Capital Life Sciences, Pura Vida Investments and Innovatus Capital Partners participated in the round.
New investors Catalio Capital Management, HealthCor Family Office, INTAI Technology Corp and Montreux Growth Partners also contributed funding.
The company also announced that it has appointed Shayce Petrovich as Vice Chairman of the Board of Directors.
Imperative Care develops technology focused on closing gaps in care for people who have suffered stroke and other vascular diseases.
The company’s Kandu Health digital health platform provides remote patient monitoring and support services to help post-stroke patients transition from hospital to home.
“We appreciate the continued support of our existing investors and welcome new investors who share our vision for leadership in stroke and vascular clot removal,” Fred Khosravi, Imperative Care’s chairman and CEO, said in a statement.
“This funding supports our rapid growth strategy to deliver better care to more patients. We will continue to invest in new technologies and clinical evidence to measure the impact these technologies have on patient outcomes.”
Scopio Labs, a Tel Aviv-based startup that offers an AI-powered digital cell morphology platform, has secured $42 million in Series D funding, bringing its total funding to $130 million.
The round was led by Fortissimo Capital, with participation from existing investors.
Scorpio Labs uses computational photography and AI to capture and analyze digital images of thousands of blood cells, the results of which the company says can support clinical decisions to enhance patient care.
The company plans to use the funds to strengthen its digital morphology platform and expand its global reach.
“Scopio is at a critical inflection point: its hematology solutions are transforming the way laboratories analyze blood samples. We believe Scopio Labs will become the new global standard in digital cell morphology,” Yuval Cohen, managing partner at Fortissimo Capital, said in a statement.
“We look forward to supporting Scopio as it grows and strengthens its leading position in the market.”
NAVIGANTIS, a health robotics company that has developed a robotic platform for neurovascular surgery, announced the completion of a $12 million Series A funding round led by Puma Venture Capital.
Cormorant Asset Management, Mirae Asset Capital, and all existing investors participated in the round.
Amit Hasan, founder and managing partner of Puma Venture Capital, will join the company’s board of directors.
The company plans to use the funding to continue developing and testing the VASCO robot and to study it in clinical trials for neurovascular surgery.
